SCHEMBL17618004

SCHEMBL17618004

NCc1cc2ccccc2[nH]c1=O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.58
ALDH1A1 P00352 5/20 0.58
HPGD P15428 1/20 0.58
LOXL2 Q9Y4K0 1/20 0.56
HSD17B10 Q99714 2/20 0.55
CYP1A2 P05177 1/20 0.55
BRD4 O60885 1/20 0.55
DAO P14920 1/20 0.55
DDO Q99489 1/20 0.55
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
IL4I1 Q96RQ9 4/20 0.52
CHEK1 O14757 1/20 0.51
KDR P35968 1/20 0.51
TSHR P16473 2/20 0.51
MAPT P10636 2/20 0.50
KMT2A Q03164 1/20 0.50
GAA P10253 1/20 0.50
HIF1A Q16665 1/20 0.50
RXFP1 Q9HBX9 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17601025 0.98 KDM4E (0.56) KDM4EALDH1A1HPGDLOXL2HSD17B10
SCHEMBL5089423 0.86 KDM4E (0.55) KDM4EALDH1A1HPGDLOXL2HSD17B10
SCHEMBL1263927 0.83 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL31154599 0.83 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL6402311 0.81 DAO (0.59) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL8873594 0.81 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL9293635 0.81 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL30162531 0.81 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL8797241 0.79 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10CYP1A2
SCHEMBL13349416 0.79 KDM4E (0.59) KDM4EALDH1A1HPGDHSD17B10CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3510404-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF Pharmakea, Inc. (US) 2019-07-17 EP claimed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 US claimed
WO-2018048928-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO claimed
US-20250129045-A1 SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA 2025-04-24 US disclosed
WO-2023150534-A1 SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2023-08-10 WO disclosed
EP-3510404-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF Pharmakea, Inc. (US) 2019-07-17 EP disclosed
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF PHARMAKEA, INC. 2019-06-27 US disclosed
US-20180134682-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2018-05-17 US disclosed
WO-2018048928-A1 CHEMICAL PROBES OF LYSYL OXIDASE-LIKE 2 AND USES THEREOF PHARMAKEA, INC. (US) 2018-03-15 WO disclosed
WO-2017197088-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS PHARMAKEA, INC. (US) 2017-11-16 WO disclosed
US-9815817-B2 Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors FORMA THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS FORMA THERAPEUTICS, INC. 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134682-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B KDM4E 2270/4885ALDH1A1 604/4885HPGD 240/4885
US-20250129045-A1 SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF PIM3, PIM1, PIM2 KDM4E 356/4885ALDH1A1 4305/4885HPGD 3831/4885
US-20160083365-A1 QUINOLINONE PYRIMIDINES COMPOSITIONS AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS IDH1, IDH3A, IDH3B KDM4E 2270/4885ALDH1A1 604/4885HPGD 240/4885
US-20190192697-A1 CHEMICAL PROBES OF LYSYL OXIDASK-LIKE 2 AND USES THEREOF LOXL2, LOXL1, LOXL3 KDM4E 3469/4885ALDH1A1 1508/4885HPGD 1188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.